This Canadian biotech stock is undervalued, analyst says

Leede analyst Doug Loe reiterated a “Speculative Buy” rating on Toronto-based Satellos Bioscience (Satellos Bioscience Stock Quote, Chart, News, Analysts, Financials TSX:MSCL) in a Feb. 9 update and revised his one-year price target to US$16.00, reflecting the company’s recently completed share consolidation and equity financing, while leaving his core clinical thesis unchanged.

Loe said recent capital structure adjustments have “minimal bearing on our investment thesis for the firm’s lead drug SAT-3247”, while materially strengthening the balance sheet and reducing financial risk. Satellos recently completed a 12-for-1 share consolidation, followed by a US$50-million equity offering, which Loe said meaningfully improves the company’s ability to fund ongoing Phase II and future Phase III clinical development.

“Our rating and the investment thesis that underpinned it are unchanged,” Loe said, adding that the financing “provides new sources of capital to fund SAT-3247 Phase II/III Duchenne muscular dystrophy testing,” allowing the focus to return to upcoming clinical catalysts.

Satellos is developing SAT-3247, a small-molecule, oral AAK1 inhibitor targeting Duchenne muscular dystrophy, with a differentiated mechanism aimed at improving muscle regeneration through muscle progenitor cells. Loe said this approach distinguishes Satellos from exon-skipping and gene-therapy competitors already on the market or in late-stage trials.

The company is currently running two Phase II DMD studies, including the LT-001 adult trial in Australia, where Loe expects interim one-year data on muscle fat fraction, regeneration markers and grip strength later this quarter, followed by periodic updates.

From a valuation standpoint, Loe said the revised target reflects the new capital structure rather than any change in clinical expectations. His updated model assumes approximately 24.1 million fully diluted shares outstanding and US$88.1 million in pro forma cash, with valuation based on a blend of risk-adjusted NPV and long-term earnings multiples. Loe maintained a 30% discount rate, which he said remains appropriate for a Phase II-stage drug developer despite reduced balance-sheet risk.

“With capital markets considerations now in the rear-view mirror, our attention shifts to imminent Phase II updates from LT-001 and BASECAMP,” Loe said. “Our investment thesis predicts a positive SAT-3247 impact on muscle physiology in DMD patients sufficient to justify progression into Phase III testing.”

At current levels, Loe said the revised target implies approximately 42% one-year upside.

Loe expects Satellos to generate negative $25.0-million in Adjusted EBITDA on nil revenue in fiscal 2025, deteriorating to approximately negative $27.8-million in Adjusted EBITDA on nil revenue in fiscal 2026, reflecting continued investment in clinical development.

-30-